Kyverna Therapeutics (KYTX) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Kyverna Therapeutics in October 2026.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Kyverna Therapeutics (KYTX) Stock Forecast
Analyst price target, next 12 months
$32.50
+422.5% vs today's $6.22
Price range over the last 12 months
Close to its 12-month low
Analysts covering Kyverna Therapeutics have a consensus 12-month target of $32.50, above the current price of $6.22.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Kyverna's stock, expecting it to rise significantly in value.
Financial Health
Kyverna Therapeutics is showing strong financial performance with good cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
